---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-267862"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-06-11T21:06:44+00:00"
generated_at: "2026-06-11T21:08:38.585376+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics stockholders approve reverse stock split at 1:10 to 1:100 ratio

## Summary
- Reverse stock split approved with 4,715,574 for, 1,517,896 against, 21,866 abstentions.
- Board authorized to determine timing and exact ratio within 1-for-10 to 1-for-100 range.
- Class I director June Bray elected with 2,430,964 votes for, 216,735 withheld; 3,607,640 broker non-votes.
- BDO USA, P.C. ratified as independent auditor for FY2026 with 6,080,608 votes for.
- Advisory vote on executive compensation approved with 2,504,778 for, 116,876 against, 26,044 abstentions.

## SEC filing metadata
- accession: 0001193125-26-267862
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-06-11T21:06:44+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/d124733d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-267862
- JSON: https://secwatch.observer/filing/0001193125-26-267862.json
- Plain text: https://secwatch.observer/filing/0001193125-26-267862.txt

## Key facts
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split at a ratio ranging from one-for-ten to one-for-one hundred at the 2026-06-11 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio ranging from one-for-ten (1-for-10) to one-for-one hundred (1-for-100) with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm BDO USA, P.C. for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Election of one Class I director to serve until the 2029 annual meeting at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s stockholders approved the election of one Class I director to the Board of Directors to serve until the 2029 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm
- Shareholder Votes
  Quince Therapeutics, Inc. shareholders approved Adjournment of Annual Meeting to permit further solicitation and vote of proxies if necessary at the 2026-06-11 meeting.
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s stockholders approved the adjournment or postponement of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in favor of the foregoing proposals.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.